^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | letrozole (Aromatase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
04/05/2018
Excerpt:
Femara is an aromatase inhibitor indicated for:...Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
Source:
Title:
Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery
Excerpt:
...The number of stained cells will be compared in tissue that is hormone receptor-positive tissue to tissue that is hormone receptor negative.`...
Trial ID:
Source:
Title:
A trial to determine the effect of glucosamine versus placebo on aromatase inhibitor induced arthralgia (joint pain) in postmenopausal women with early breast cancer who are on letrozole
Excerpt:
...Patients must have histologically or cytologically confirmed hormone receptor positive early breast cancer in whom adjuvant treatment with letrozole is planned (initial, switch or extended situations allowed, provided no prior aromatase inhibitor had been used). ...
Trial ID:
More C2 evidence
Source:
Title:
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Excerpt:
...- Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer...
Trial ID:
Source:
Title:
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
Excerpt:
...- Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone receptor), determined by immunohistochemistry, after primary surgery and before commencement of prior endocrine therapy...
Trial ID:
Source:
Title:
Clinical study for postmenopausal patients with early breast cancer treated with letrozole for 5 years and withdrawal of 3 months plus transdermal estrogen therapy. Studio clinico per pazienti in postmenopausa operate di tumore mammario candidate ad un trattamento con letrozolo per 5 anni con sospensione di tre mesi e terapia estrogenica somministrata per via transdermica.
Excerpt:
...- Diagnosis of hormone receptor positive tumors. ...
Trial ID:
Source:
Title:
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
Excerpt:
...Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies, with hormone receptor positive and human epidermal growth factor receptor 2 negative confirmed by tumor histopathology and molecular pathology....
Trial ID:
Source:
Title:
Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene
Excerpt:
...Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Complete 5 Years of Toremifene in 30 months 6....
Trial ID:
Source:
Title:
Dalpiciclib and letrozole combined with trastuzumab / pertuzumab in neoadjuvant treatment of stage II-III HR positive HER2 positive breast cancer: a phase Ib/II study
Excerpt:
......
Trial ID:
Less C2 evidence
Source:
Title:
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
Published date:
08/23/2016
Excerpt:
Letrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.
DOI:
10.4143/crt.2016.259
